Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open- label, phase II trial

DSpace Repository

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open- label, phase II trial

Author: Chesney, Jason A.; Puzanov, Igor; Collichio, Frances A.; Singh, Parminder; Milhem, Mohammed M.; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore; Hauschild, Axel; Lebbe, Celeste; Joshi, Harshada; Snyder, Wendy; Mehnert, Janice M.
Tübinger Autor(en):
Garbe, Claus
Published in: Journal For Immunotherapy of Cancer (2023), Bd. 11 (5), Article e006270
Verlagsangabe: Bmj Publishing Group
Language: English
Full text: http://dx.doi.org/10.1136/jitc-2022-006270
ISSN: 2051-1426
DDC Classifikation: 570 - Life sciences; biology
610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)